SAXOL | Linksium
Back to portfolio

SAXOL

Maturation

A new therapeutic agent with dual properties: it synergises taxanes and protects against chemo-induced neuropathy

profilePhoto   Elodie Lages
Linksium Contact Elodie Lages +33 (0)7 76 23 29 19 elodie.lages@linksium.fr
Visuel SAXOL

Benefits

  • Reduction of taxane doses without loss of therapeutic efficacy
  • Reduced toxicity
  • Prevention of chemo-induced peripheral neuropathy

Key words

  • Taxane chemotherapy
  • Peripheral neuropathies
  • Cancer

Intellectual Property

  • 1 patent

Laboratory

  • IAB

Institutions

  • CNRS
  • INSERM
  • UGA

Linksium Continuum

  • Maturation

Results

  • Available licenses

Context

Taxane-based chemotherapies are among the most frequently used cancer therapies. However, they have adverse effects such as neuropathy (CIPN), which have a major impact on patients' quality of life. These neuropathies are often the cause of treatment discontinuation and compromise the success of the cancer treatment. In 1 out of 4 cases, they may even persist irremediably.

Technology

SAXOL project is based on the discovery of Carba1, which acts in synergy with Taxol®, allowing doses to be reduced while maintaining its therapeutic effectiveness. It also activates a metabolic enzyme, which has a neuroprotective effect.

Advantages

  • Reduction of taxane doses for a preserved therapeutic effect: limitation of toxicities due to taxane formulations, reduction of resistance.
  • Neuroprotective effect preventing the onset of neuropathies for which there is no effective preventive treatment.

State of progress

  • Validated and patented method for the synthesis of Carba1
  • Synergistic effect of the Carba1/Taxol combination validated in vivo in a mouse tumour model
  • ADME-Tox: performed, no warning signals
  • Neuroprotection: demonstrated on neurons in vitro. Target and mechanism of action known.

Applications

  • Cancer chemotherapy
  • Prevention of chemo-induced peripheral neuropathy
  • Potential prevention of other neuropathies (diabetes) and neurodegenerative diseases

Featured articles

Nora Dempsey and deeptech innovations

1, 2 and 3 startups for Nora Dempsey, National Medal of Innovation 2021

Nora Dempsey is one of the four winners of National Medal for Innovation 2021 awarded by CNRS. Nora Dempsey, born in Ireland, has gained an international recognition for her research in Grenoble on...

Read the article
Dd amiral 2018 Frenchweb

Amiral Technologies, la startup IA grenobloise spécialisée dans les solutions de maintenance prédictive, intègre Station F

An ambitious promise: to invent a zero-defect and zero-downtime future for industry. Amiral Technologies, a startup co-founded and boosted by Linksium, based on the technological prowess of the Gre...

Read the article
Close projects index

U

X